---
title: "InMed amends merger deal with Mentari, files S-4 registration statement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292353581.md"
description: "InMed Pharmaceuticals amended its all-stock merger agreement with Mentari Therapeutics to clarify deal sequencing, exchange-ratio effects from pre-closing financing, and tax treatment. The company filed a Form S-4 registration statement, including a preliminary proxy statement/prospectus. Both firms aim to close the transaction in Q4 2026, pending shareholder approvals and other customary conditions."
datetime: "2026-07-10T20:03:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292353581.md)
  - [en](https://longbridge.com/en/news/292353581.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292353581.md)
---

# InMed amends merger deal with Mentari, files S-4 registration statement

-   InMed’s all-stock merger with privately held Mentari Therapeutics was amended to clarify deal sequencing, exchange-ratio effects from pre-closing financing, and intended tax treatment. \* A registration statement on Form S-4 was filed, including a preliminary proxy statement/prospectus and management information circular for the transaction. \* The companies continue to target closing in Q4 2026, subject to shareholder and stockholder votes and other customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-077127), on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [INM.US](https://longbridge.com/en/quote/INM.US.md)

## Related News & Research

- [Mentari Therapeutics merger with InMed set to close ahead of USD 200 million private placement](https://longbridge.com/en/news/293462774.md)
- [InMed Pharmaceuticals amends merger pact with Mentari Therapeutics](https://longbridge.com/en/news/291880249.md)
- [FDCTech delays Q2 10-Q filing, cites pending foreign subsidiary tax information](https://longbridge.com/en/news/296088870.md)
- [UFLEX: Q1 FY27 saw robust revenue and profit growth, with new recycling operations and ongoing tax appeals](https://longbridge.com/en/news/296057440.md)
- [Suzano names Walner Junior executive vice president for legal, tax and corporate affairs](https://longbridge.com/en/news/296133284.md)